|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
MA42447A
(fr)
|
2015-07-13 |
2018-05-23 |
Cytomx Therapeutics Inc |
Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
|
|
US12030942B2
(en)
|
2015-10-02 |
2024-07-09 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
EA201891165A1
(ru)
|
2015-11-18 |
2018-11-30 |
Мерк Шарп И Доум Корп. |
Молекулы, связывающие pd1 и/или lag3
|
|
SG11201809627QA
(en)
|
2016-05-18 |
2018-12-28 |
Boehringer Ingelheim Int |
Anti pd-1 and anti-lag3 antibodies for cancer treatment
|
|
EP3458485B1
(en)
|
2016-05-19 |
2021-12-29 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
|
|
CN117586403A
(zh)
|
2016-10-11 |
2024-02-23 |
艾吉纳斯公司 |
抗lag-3抗体及其使用方法
|
|
PE20190911A1
(es)
|
2016-10-13 |
2019-06-26 |
Symphogen As |
Composiciones y anticuerpos anti-lag-3
|
|
US11359018B2
(en)
|
2016-11-18 |
2022-06-14 |
Symphogen A/S |
Anti-PD-1 antibodies and compositions
|
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
|
KR102813603B1
(ko)
|
2017-02-10 |
2025-05-29 |
리제너론 파마슈티칼스 인코포레이티드 |
면역-pet 이미지화를 위한 방사선 라벨링된 항-lag3 항체
|
|
JP2020516604A
(ja)
*
|
2017-04-05 |
2020-06-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗がん併用療法
|
|
US11939380B2
(en)
|
2017-04-05 |
2024-03-26 |
Les Laboratoires Servier |
Combination therapies targeting PD-1, TIM-3, and LAG-3
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
AU2018263868A1
(en)
|
2017-05-02 |
2019-12-12 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
|
JP2020522691A
(ja)
|
2017-05-30 |
2020-07-30 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｌａｇ−３陽性腫瘍の処置
|
|
CN110678200B
(zh)
|
2017-05-30 |
2024-05-17 |
百时美施贵宝公司 |
包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
|
|
EP3630842A2
(en)
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
|
MX2019014199A
(es)
*
|
2017-06-02 |
2020-01-23 |
Boehringer Ingelheim Int |
Tratamiento de combinacion antineoplasico.
|
|
AU2018391217A1
(en)
*
|
2017-12-22 |
2020-07-09 |
Jiangsu Hengrui Medicine Co., Ltd. |
LAG-3 antibody pharmaceutical composition and use thereof
|
|
CN109970856B
(zh)
*
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
KR102839330B1
(ko)
|
2018-01-15 |
2025-07-30 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-1에 대한 단일-도메인 항체 및 이의 변이체
|
|
US20210363243A1
(en)
*
|
2018-02-01 |
2021-11-25 |
Merck Sharp & Dohme Corp. |
Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
|
|
WO2019165195A1
(en)
*
|
2018-02-22 |
2019-08-29 |
Srivastava Satish |
Combination therapy for the treatment of cancer
|
|
FR3078536A1
(fr)
*
|
2018-03-05 |
2019-09-06 |
Peptinov Sas |
Composition vaccinale anti-pd-1
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
US20210024873A1
(en)
|
2018-03-27 |
2021-01-28 |
Bristol-Myers Squibb Company |
Real-time monitoring of protein concentration using ultraviolet signal
|
|
WO2019217457A1
(en)
|
2018-05-07 |
2019-11-14 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
EP3814379A4
(en)
|
2018-05-07 |
2022-03-30 |
Genmab A/S |
METHOD OF TREATMENT OF CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
JP2021527082A
(ja)
*
|
2018-06-11 |
2021-10-11 |
イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ |
新規な免疫チェックポイント阻害剤
|
|
SG11202100693UA
(en)
|
2018-07-26 |
2021-02-25 |
Bristol Myers Squibb Co |
Lag-3 combination therapy for the treatment of cancer
|
|
LT3866850T
(lt)
|
2018-10-19 |
2024-09-10 |
Bristol-Myers Squibb Company |
Kompleksinė melanomos terapija
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
EP3880709A4
(en)
*
|
2018-11-05 |
2022-07-27 |
Merck Sharp & Dohme Corp. |
DOSING REGIME OF ANTI-LAG3 ANTIBODIES AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODIES FOR THE TREATMENT OF CANCER
|
|
CA3118144A1
(en)
*
|
2018-11-07 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
|
WO2020097141A1
(en)
|
2018-11-07 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
|
|
TWI894135B
(zh)
|
2019-01-25 |
2025-08-21 |
德商百靈佳殷格翰國際股份有限公司 |
編碼ccl21之重組棒狀病毒
|
|
WO2020172658A1
(en)
|
2019-02-24 |
2020-08-27 |
Bristol-Myers Squibb Company |
Methods of isolating a protein
|
|
US11578129B2
(en)
*
|
2019-03-29 |
2023-02-14 |
Boehringer Ingelheim International Gmbh |
LRP5 and PD-1 antagonist anticancer combination therapy
|
|
BR112021016520A2
(pt)
*
|
2019-03-29 |
2021-10-26 |
Boehringer Ingelheim International Gmbh |
Terapia de combinação anticâncer
|
|
EP3947640A4
(en)
|
2019-04-02 |
2022-12-14 |
The Brigham & Women's Hospital, Inc. |
PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA
|
|
AU2020276242B2
(en)
*
|
2019-05-13 |
2025-01-30 |
Regeneron Pharmaceuticals, Inc. |
Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
|
|
KR20220012292A
(ko)
|
2019-05-23 |
2022-02-03 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 배양 배지를 모니터링하는 방법
|
|
KR20220016157A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 국재화 시그너쳐 및 조합 요법
|
|
CN114174538A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
适合于免疫肿瘤学疗法的多肿瘤基因特征
|
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
EP3983450A4
(en)
*
|
2019-06-12 |
2023-07-05 |
Nanjing GenScript Biotech Co., Ltd. |
ANTI-PD-L1/ANTI-LAG-3 PROTEINS WITH MULTIPLE ANTIGEN BINDING AND METHODS FOR THEIR USE
|
|
CN112121169B
(zh)
*
|
2019-06-24 |
2023-10-24 |
广州再极医药科技有限公司 |
用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂
|
|
WO2021006199A1
(ja)
|
2019-07-05 |
2021-01-14 |
小野薬品工業株式会社 |
Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
WO2021005546A1
(en)
|
2019-07-09 |
2021-01-14 |
Cadila Healthcare Limited |
Antibodies to human programmed death receptor pd-1
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
WO2021025140A1
(ja)
|
2019-08-08 |
2021-02-11 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
|
CN111420049A
(zh)
*
|
2019-08-22 |
2020-07-17 |
Biocad股份公司 |
抗-pd1抗体prolgolimab的水性药物组合物及其应用
|
|
MX2022003001A
(es)
*
|
2019-09-11 |
2022-04-07 |
Boehringer Ingelheim Io Canada Inc |
Metodos para tratar el cancer mediante el uso de inhibidores del eje de pd-1 y anticuerpos anti-periostina.
|
|
JP2022549273A
(ja)
|
2019-09-22 |
2022-11-24 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング
|
|
TWI878355B
(zh)
|
2019-10-02 |
2025-04-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
CA3160479A1
(en)
|
2019-11-08 |
2021-05-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
|
CN110950966B
(zh)
*
|
2019-12-13 |
2020-12-11 |
启辰生生物科技(珠海)有限公司 |
融合蛋白、编码核酸和细胞及用途
|
|
JP2023514152A
(ja)
|
2020-02-06 |
2023-04-05 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｉｌ－１０およびその使用
|
|
WO2021245111A1
(en)
|
2020-06-03 |
2021-12-09 |
Boehringer Ingelheim International Gmbh |
Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein
|
|
CN114605544B
(zh)
*
|
2020-06-05 |
2023-08-01 |
北京天广实生物技术股份有限公司 |
Lag3抗体及其用途
|
|
CA3182579A1
(en)
|
2020-07-07 |
2022-01-13 |
Ugur Sahin |
Therapeutic rna for hpv-positive cancer
|
|
EP4204095A1
(en)
|
2020-08-28 |
2023-07-05 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
|
KR20230061430A
(ko)
|
2020-08-31 |
2023-05-08 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 국재화 시그너쳐 및 면역요법
|
|
BR112023005377A2
(pt)
|
2020-09-24 |
2023-04-25 |
Merck Sharp & Dohme Llc |
Formulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e variantes de hialuronidase e fragmentos das mesmas e métodos de uso das mesmas
|
|
CN116406369A
(zh)
|
2020-10-05 |
2023-07-07 |
百时美施贵宝公司 |
用于浓缩蛋白质的方法
|
|
KR20230093282A
(ko)
|
2020-10-23 |
2023-06-27 |
브리스톨-마이어스 스큅 컴퍼니 |
폐암에 대한 lag-3 길항제 요법
|
|
CN117580859A
(zh)
|
2020-11-17 |
2024-02-20 |
思进股份有限公司 |
用图卡替尼和抗pd-1/抗pd-l1抗体的组合治疗癌症的方法
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
AU2021411486A1
(en)
|
2020-12-28 |
2023-06-29 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
EP4267172A1
(en)
|
2020-12-28 |
2023-11-01 |
Bristol-Myers Squibb Company |
Subcutaneous administration of pd1/pd-l1 antibodies
|
|
US20240384350A1
(en)
|
2021-01-29 |
2024-11-21 |
Board Of Regents, The University Of Texas System |
Methods of treating cancer with kinase inhibitors
|
|
IL307262A
(en)
|
2021-03-29 |
2023-11-01 |
Juno Therapeutics Inc |
METHODS FOR DOSAGE AND THERAPY IN COMBINATION OF CHECKPOINT INHIBITOR AND CAR T CELL THERAPY
|
|
WO2022216979A1
(en)
|
2021-04-08 |
2022-10-13 |
Board Of Regents, The University Of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
EP4337694A1
(en)
|
2021-05-12 |
2024-03-20 |
Dana-Farber Cancer Institute, Inc. |
Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
|
|
EP4355778A1
(en)
|
2021-06-17 |
2024-04-24 |
Boehringer Ingelheim International GmbH |
Novel tri-specific binding molecules
|
|
EP4370552A1
(en)
|
2021-07-13 |
2024-05-22 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
IL311771A
(en)
|
2021-10-06 |
2024-05-01 |
BioNTech SE |
Multispecific binding agents against pd-l1 and cd137 in combination
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
IL309227A
(en)
|
2021-10-29 |
2024-02-01 |
Bristol Myers Squibb Co |
LAG-3 antagonist therapy for hematological cancer
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
EP4469477A1
(en)
|
2022-01-26 |
2024-12-04 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
|
AU2023226078A1
(en)
|
2022-02-25 |
2024-08-22 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma.
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
CN119156403A
(zh)
|
2022-03-08 |
2024-12-17 |
阿伦蒂斯治疗股份公司 |
抗紧密连接蛋白-1抗体增加t细胞可用性的用途
|
|
KR20240156411A
(ko)
|
2022-03-09 |
2024-10-29 |
브리스톨-마이어스 스큅 컴퍼니 |
치료 단백질의 일시적 발현
|
|
US20250206775A1
(en)
|
2022-03-18 |
2025-06-26 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
WO2023183317A2
(en)
*
|
2022-03-21 |
2023-09-28 |
Ab Therapeutics, Inc. |
Multispecific antibodies and uses thereof
|
|
TW202413412A
(zh)
|
2022-05-12 |
2024-04-01 |
丹麥商珍美寶股份有限公司 |
在組合療法中能夠結合到ｃｄ２７之結合劑
|
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
AU2023305094A1
(en)
|
2022-07-15 |
2025-01-16 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
|
AU2023401158A1
(en)
|
2022-12-01 |
2025-05-29 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
|
TW202440157A
(zh)
|
2022-12-01 |
2024-10-16 |
英商梅迪繆思有限公司 |
用於治療癌症的組合療法
|
|
KR20250120305A
(ko)
|
2022-12-14 |
2025-08-08 |
아스텔라스 파마 유럽 비.브이. |
Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
|
|
US20260000757A1
(en)
|
2022-12-21 |
2026-01-01 |
Bristol-Myers Squibb Company |
Combination therapy for lung cancer
|
|
KR20250136390A
(ko)
|
2023-01-20 |
2025-09-16 |
베링거 인겔하임 인터내셔날 게엠베하 |
IL-12 Fc 융합 단백질
|
|
US20240299601A1
(en)
|
2023-02-17 |
2024-09-12 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
|
CN115960834B
(zh)
*
|
2023-03-07 |
2023-06-09 |
浙江省肿瘤医院 |
一种pd-1/ptx联合pd-1耐药模型建立的方法
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2024209072A1
(en)
|
2023-04-06 |
2024-10-10 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 for treating cancer
|
|
US12410258B2
(en)
|
2023-05-12 |
2025-09-09 |
Ganmab A/S |
Antibodies capable of binding to OX40, variants thereof and uses thereof
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
TW202535926A
(zh)
|
2023-10-30 |
2025-09-16 |
美商再生元醫藥公司 |
穩定抗體配製物
|
|
WO2025114541A1
(en)
|
2023-11-30 |
2025-06-05 |
Genmab A/S |
Antibodies capable of binding to ox40 in combination therapy
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025132695A1
(en)
|
2023-12-19 |
2025-06-26 |
Boehringer Ingelheim International Gmbh |
Recombinant rhabdovirus encoding for a gasdermin
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
EP4658320A1
(en)
|
2024-02-27 |
2025-12-10 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
WO2025202213A1
(en)
|
2024-03-26 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
|
|
WO2025226695A1
(en)
|
2024-04-23 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|